Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study

What this Trial Is About

This research aims to compare serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) among adult male participants with methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy controls. The study also evaluates systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examines links between these biomarkers and clinical symptom severity, including insight and psychotic symptoms measured by specific scales. This observational case-control study is conducted in accordance with ethical guidelines and involves participants aged 18 to 65 years. Participants include adult males diagnosed with MUD or MP based on DSM-5-TR criteria and healthy adults without psychiatric or significant medical conditions. Blood samples are collected at hospital admission before treatment begins to measure serum LRFN5, OLFM4, and inflammatory markers. Psychotic symptom severity and insight are assessed in the MP group using the Positive and Negative Syndrome Scale (PANSS) and Insight Assessment Scale (IAS). Sociodemographic and clinical data are recorded for all groups. The healthy control recruitment was completed by January 2026. Participants provide informed consent and undergo baseline clinical evaluation including blood sampling and questionnaire assessments where applicable. Researchers collect data on medical history, drug use, and smoking status. The main outcomes measured are serum levels of LRFN5 and OLFM4, systemic inflammation index, and psychotic symptom scales. This study does not involve assigned interventions and aims to better understand biological markers related to methamphetamine-induced psychosis over the recruitment period ending in April 2026.

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis